These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24843615)

  • 1. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).
    Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A
    Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
    Hou L; Zhao T; Liu Y; Zhang Y
    Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
    Kashiwagi A; Kadowaki T; Tajima N; Nonaka K; Taniguchi T; Nishii M; Ferreira JC; Amatruda JM
    J Diabetes Investig; 2011 Oct; 2(5):381-90. PubMed ID: 24843518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials.
    Ommen ES; Xu L; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Ther; 2015 Mar; 6(1):29-40. PubMed ID: 25633134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
    Kanamori A; Matsuba I
    J Clin Med Res; 2013 Jun; 5(3):217-21. PubMed ID: 23671547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
    Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Ther; 2015 Jun; 6(2):213-26. PubMed ID: 26014844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
    Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H;
    J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks.
    Hamaguchi T; Koga M; Murai J; Saito H; Tamada D; Kurebayashi S; Katsuno T; Miyagawa J; Namba M
    J Diabetes Investig; 2012 Mar; 3(2):175-8. PubMed ID: 24843562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
    Bando Y; Kanehara H; Aoki K; Hisada A; Toya D; Tanaka N
    J Diabetes Investig; 2012 Mar; 3(2):170-4. PubMed ID: 24843561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.
    Kadowaki T; Tajima N; Odawara M; Nishii M; Taniguchi T; Ferreira JC
    J Diabetes Investig; 2013 Mar; 4(2):174-81. PubMed ID: 24843649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.
    Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
    Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of initial Basal-supported oral therapy with sitagliptin in untreated type 2 diabetes.
    Yoshioka K
    Diabetes Ther; 2013 Dec; 4(2):409-16. PubMed ID: 24127136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.
    Kubota A; Yabe D; Kanamori A; Kuroe A; Takahashi N; Saito T; Matsuba I; Nabe K; Kurose T; Seino Y
    J Diabetes Investig; 2014 Jul; 5(4):445-8. PubMed ID: 25411605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.